Fig. 4

Affect of 1,4-dihydroxy quininib alone and in combination on dendritic cell markers. Monocyte-derived dendritic cells were co-cultured with tumor conditioned media generated from resected patient CRC tissue. Flow cytometry analysis was used to determine expression levels of 8 dendritic cell markers. Stimulation with LPS (to induce DC maturation) significantly increased the expression of all 8 DC surface markers (*p < 0.05, **p < 0.01). a Combination treatment of 1,4-dihydroxy quininib with FOLFOX significantly increased HLA-DR expression (p < 0.05, FC = 1.1), b The expression level of CD11c significantly increased compared to LPS control following treatment with 1,4-dihydroxy quininib (p < 0.01, FC = 1.4), 1,4-dihydroxy quininib combined with Bevacizumab (p < 0.01, FC = 1.1), FOLFOX (p < 0.05, FC = 1.2), and 1,4-dihydroxy quininib in combination with FOLFOX (p < 0.01, FC = 1.3). c CD86 expression significantly increased compared to LPS control (p < 0.05, FC = 1.2). d PDL-1 expression level significantly increased compared to LPS control following treatment with FOLFOX (p < 0.01, FC = 1.2). e The expression of CD40 significantly decreased compared to LPS control following treatment with 1,4-dihydroxy quininib in combination with Bevacizumab (p < 0.05, FC = 1.1) and 1,4-dihydroxy quininib in combination with FOLFOX (p < 0.01, FC = 1.2). f CD80 expression significantly decreased compared to LPS control following treatment with 1,4-dihydroxy quininib in combination with FOLFOX (p < 0.01, FC = 1.1). g CD83 expression significantly decreased compared to LPS control following treatment with 1,4-dihydroxy quininib in combination with Bevacizumab (p < 0.05, FC = 1.2), and 1,4-dihydroxy quininib in combination with FOLFOX (p < 0.01, FC = 1.1). h CD54 expression significantly decreased compared to LPS control following treatment with 1,4-dihydroxy quininib in combination with Bevacizumab (p < 0.05, FC = 1.1). Statistical analysis was performed using Wilcoxon signed rank test to determine significance between groups. (*p < 0.05, **p < 0.01). ‘-’ denotes no LPS stimulation while ‘+’ denotes LPS stimulation. 1,4-dihydrox. Quin. = 1,4-dihydroxy quininib, Bev = Bevacizumab, FC = Fold Change. Error bars represent mean SEM